Accession Number:

ADA610560

Title:

An In Vivo shRNA-Drug Screen to Identify Novel Targeted Therapy Combinations for KRAS Mutant Cancers

Descriptive Note:

Annual rept. 1 September 2012 to 31 August 2013

Corporate Author:

MASSACHUSETTS GENERAL HOSPITAL BOSTON

Personal Author(s):

Report Date:

2013-09-01

Pagination or Media Count:

9.0

Abstract:

The primary shRNA-drug screen utilizing PDAC cell lines has been completed. The top 100 gene targets that specifically cooperate with MEK inhibitors were prioritized using the statistical RNAi gene enrichment ranking RIGER algorithm, which considers all shRNAs against a specific gene as a hairpin set . Construction of the inducible shRNA mini-pool based on the top 100 gene hits from the primary screen is currently underway. Upon completion, this shRNA mini-pool will be utilized to perform the secondary shRNA-drug screen in an orthotopic mouse pancreatic cancer model as originally proposed.

Subject Categories:

  • Genetic Engineering and Molecular Biology

Distribution Statement:

APPROVED FOR PUBLIC RELEASE